Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05417711
Other study ID # 2022-KY-074
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 23, 2023
Est. completion date September 1, 2026

Study information

Verified date November 2023
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Yuexin Cai Cai, Doctor
Phone +8613825063663
Email panada810456@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical study is a prospective, multicenter, randomized, controlled, double-blind clinical study. Sun Yat Sen Memorial Hospital of Sun Yat sen University was the central unit, and Nanjing First Hospital, Sun Yat Sen people's Hospital, Guanfzhou Panyu central Hospital and Zhuhai integrated traditional Chinese and Western medicine hospital were the cooperative units. In this study, 388 patients with chronic subjective tinnitus were recruited. In view of chronic subjective tinnitus, a common ear disease, the study gave the patients three months of treatment with transcutaneous vagus nerve stimulation paired with tailor-made notched music therapy or tailor-made notched music training alone. By comparing the changes of subjective scale scores related to tinnitus before and after treatment in patients receiving two different therapies, such as THI, VAS, BAI, BDI, PSQI, to evaluate the efficacy of the two therapies, so as to judge whether transcutaneous vagus nerve stimulation paired with tailor-made notched music therapy is better than tailor-made notched music training alone. In addition, the study will continue to follow up the patients after the treatment for one year to observe the difference in the long-term sustained efficacy of the two therapies. This clinical study will also evaluate the two therapies from the perspective of compliance and safety, and explore the factors that affect the efficacy of the two therapies.


Description:

Unified rules for filling in case report forms: - All case report forms must be completed by designated and trained researchers. - Two data managers independently input and proofread the data in duplicate. - The data manager will modify, confirm and enter the data according to the scales written by participant. - The locked data file will not be changed. - Use medical terms / concepts to record AES . The type, degree, occurrence time, duration, treatment measures and treatment process shall be recorded in detail. Sample size estimation: - △ THI≥ 7 points in the comparison between groups indicates that the difference in efficacy has clinical significance, the superiority margin is established. - The pre-test results showed that △ THI = -10.2 points, SD = 10.0 points in the two groups after the treatment. - According to unilateral inspection standard α= 0.025, inspection efficacy 1- β= 0.80, using two sample t-test to estimate the sample size, the results show that at least 155 subjects are included in each group. - Further estimation was made according to the loss of follow-up rate of 20%. Finally, at least 194 subjects (388 persons in total) should be included in each group. - PASS 21.0.03 (NCSs, LLC, Kaysville, Utah, USA) is adopted for the above calculation. Plan for missing data: - If the subject uses the drugs, treatment or surgery prohibited in the protocol, the subject will no longer meet the conditions of the clinical study and will be deemed to have withdrawn from the study. - If the event occurs before 3 months of treatment, the subject's data will no longer be used for statistical analysis of subsequent data. - If the event occurs in the follow-up period after the completion of treatment, the data of the subject before and after treatment shall be retained. The data in the follow-up period shall be regarded as missing data and filled with corresponding methods for full analysis set analysis. - For the missing data caused by the loss of follow-up, this study will use the method of multiple imputation to estimate the missing value. - The research subjects who failed in screening will provide corresponding treatment according to their own conditions and clinical guidelines. These subjects will not be included in the clinical study. Statistical analysis plan: When considering the influence of baseline, the continuous variables were analyzed by covariance analysis, and the qualitative indicators were tested by CMH test or logistic regression. Primary analysis: Using covariance analysis to compare the different changes of THI scores between two groups after 3-month treatment, controlled for age and baseline THI. Secondary analysis: Using covariance analysis to compare the different changes of VAS, BAI, BDI, PSQI scores between two groups after 3-month treatment, controlled for age and baseline values corresponding to each scale. Using a repeated measure ANOVA to compare the different changes of THI, VAS, BAI, BDI, PSQI between two groups at 3, 6 and 12 follow-up visits. Using Chi square test or Fisher exact test to compare the different efficient rate between two groups after 3-month treatment. Exploratory analysis: Using multiple linear regression analysis to explore the factors affecting the short-term and long -term efficacy of the two treatments, such as age, hearing loss threshold, tinnitus loudness, tinnitus frequency and so on. Using Independent two sample t-test or nonparametric analysis to compare the differences in EEG- or fMRI-related indicators between two groups. Safety analysis: Using Pearson's chi-square test to compare the difference of adverse event incidence rate between two groups.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 388
Est. completion date September 1, 2026
Est. primary completion date January 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Patients with tinnitus as the main complaint: the patients subjectively feel the sound in the ear or deep part of the head without internal or external sound stimulation, and therefore seek medical treatment - Chronic (= 6 months) and tonal tinnitus - Age 18-60 - Tinnitus frequency is 125-8000 Hz - Hearing threshold at each frequency shall not exceed 70 dB HL Exclusion Criteria: - Patients with conductive deafness, history of middle ear surgery, pulsatile tinnitus caused by vascular distortion and tinnitus caused by Meniere disease - History of head trauma, central nervous system diseases, mental diseases and drug abuse

Study Design


Intervention

Device:
Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy
The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.
Tailor-made Notched Music Training
Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.

Locations

Country Name City State
n/a

Sponsors (9)

Lead Sponsor Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Affiliated Zhuhai Hospital of Southern Medical University, Eighth Affiliated Hospital, Sun Yat-sen University, Guangzhou Panyu Central Hospital, Second Affiliated Hospital of Guangzhou Medical University, Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University, Southern Medical University, China, The First Affiliated Hospital with Nanjing Medical University, Zhongshan People's Hospital, Guangdong, China

References & Publications (16)

??? ? ?. ????«????????» [J]. ???????, 2016, 14(2): 4

???, ??, ???, et al. ???????????????????? [J]. ??? ?????????, 2021, 35(02): 105-8.

???, ???, ???, et al. ??????????????????? [J]. ???????, 2017, 15(04): 465-70.

Clancy JA, Mary DA, Witte KK, Greenwood JP, Deuchars SA, Deuchars J. Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity. Brain Stimul. 2014 Nov-Dec;7(6):871-7. doi: 10.1016/j.brs.2014.07.031. Epub 2014 Jul 16. — View Citation

Henry JA, Reavis KM, Griest SE, Thielman EJ, Theodoroff SM, Grush LD, Carlson KF. Tinnitus: An Epidemiologic Perspective. Otolaryngol Clin North Am. 2020 Aug;53(4):481-499. doi: 10.1016/j.otc.2020.03.002. Epub 2020 Apr 30. — View Citation

Langguth B, Elgoyhen AB, Cederroth CR. Therapeutic Approaches to the Treatment of Tinnitus. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:291-313. doi: 10.1146/annurev-pharmtox-010818-021556. Epub 2018 Jul 25. — View Citation

Okamoto H, Stracke H, Stoll W, Pantev C. Listening to tailor-made notched music reduces tinnitus loudness and tinnitus-related auditory cortex activity. Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1207-10. doi: 10.1073/pnas.0911268107. Epub 2009 Dec 28. — View Citation

Piccirillo JF, Rodebaugh TL, Lenze EJ. Tinnitus. JAMA. 2020 Apr 21;323(15):1497-1498. doi: 10.1001/jama.2020.0697. No abstract available. — View Citation

Rammo R, Ali R, Pabaney A, Seidman M, Schwalb J. Surgical Neuromodulation of Tinnitus: A Review of Current Therapies and Future Applications. Neuromodulation. 2019 Jun;22(4):380-387. doi: 10.1111/ner.12793. Epub 2018 Jul 17. — View Citation

Shim HJ, Kwak MY, An YH, Kim DH, Kim YJ, Kim HJ. Feasibility and Safety of Transcutaneous Vagus Nerve Stimulation Paired with Notched Music Therapy for the Treatment of Chronic Tinnitus. J Audiol Otol. 2015 Dec;19(3):159-67. doi: 10.7874/jao.2015.19.3.159. Epub 2015 Dec 18. — View Citation

Stein A, Engell A, Junghoefer M, Wunderlich R, Lau P, Wollbrink A, Rudack C, Pantev C. Inhibition-induced plasticity in tinnitus patients after repetitive exposure to tailor-made notched music. Clin Neurophysiol. 2015 May;126(5):1007-15. doi: 10.1016/j.clinph.2014.08.017. Epub 2014 Sep 6. — View Citation

Stein A, Wunderlich R, Lau P, Engell A, Wollbrink A, Shaykevich A, Kuhn JT, Holling H, Rudack C, Pantev C. Clinical trial on tonal tinnitus with tailor-made notched music training. BMC Neurol. 2016 Mar 17;16:38. doi: 10.1186/s12883-016-0558-7. — View Citation

Stockdale D, McFerran D, Brazier P, Pritchard C, Kay T, Dowrick C, Hoare DJ. An economic evaluation of the healthcare cost of tinnitus management in the UK. BMC Health Serv Res. 2017 Aug 22;17(1):577. doi: 10.1186/s12913-017-2527-2. — View Citation

Tyler R, Cacace A, Stocking C, Tarver B, Engineer N, Martin J, Deshpande A, Stecker N, Pereira M, Kilgard M, Burress C, Pierce D, Rennaker R, Vanneste S. Vagus Nerve Stimulation Paired with Tones for the Treatment of Tinnitus: A Prospective Randomized Double-blind Controlled Pilot Study in Humans. Sci Rep. 2017 Sep 20;7(1):11960. doi: 10.1038/s41598-017-12178-w. — View Citation

Yakunina N, Nam EC. Direct and Transcutaneous Vagus Nerve Stimulation for Treatment of Tinnitus: A Scoping Review. Front Neurosci. 2021 May 28;15:680590. doi: 10.3389/fnins.2021.680590. eCollection 2021. — View Citation

Yap JYY, Keatch C, Lambert E, Woods W, Stoddart PR, Kameneva T. Critical Review of Transcutaneous Vagus Nerve Stimulation: Challenges for Translation to Clinical Practice. Front Neurosci. 2020 Apr 28;14:284. doi: 10.3389/fnins.2020.00284. eCollection 2020. — View Citation

* Note: There are 16 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of treatment-related adverse events Treatment related adverse events in two groups include: auditory system related adverse reactions caused by treatment, such as auricle burn, earache, hearing loss, tinnitus aggravation, and head injury Dizziness, headache, palpitation, vomiting and other non auditory system related adverse reactions. Incidence of adverse events = number of treatment-related adverse events during treatment / total number of participants in treatment. From baseline to 12-month follow-up visit
Primary Changes in Tinnitus Handicap Inventory (THI) scores for short-term efficacy assessment Difference in the change of THI scores between two groups after 3-month treatment. The THI evaluates the severity of tinnitus in terms of emotion and function. The global scores of THI range from 0 (no disability) to 100 (serve disability). From baseline to 3-month follow-up visit
Secondary Changes in scores of Visual Analog Scale (VAS) for short-term efficacy assessment Difference in the change of VAS scores between two groups after 3-month treatment. The total VAS scores range from 0 (negligible) to 10 (too nosiy to tolerate), reflecting the loudness of tinnitus patients feel. From baseline to 3-month follow-up visit
Secondary Changes in scores of Beck Anxiety Inventory (BAI) for short-term efficacy assessment Difference in the change of BAI scores between two groups after 3-month treatment. The total BAI scores range from 0 (normal) to 63 (serve anxiety), reflecting the degree of anxiety. From baseline to 3-month follow-up visit
Secondary Changes in scores of Beck Depression Inventory (BDI) for short-term efficacy assessment Difference in the change of BDI scores between two groups after 3-month treatment. The total BDI scores range from 0 (normal) to 63 (serve depression), reflecting the degree of depression. From baseline to 3-month follow-up visit
Secondary Changes in scores of Pittsburgh sleep quality index (PSQI) for short-term efficacy assessment Difference in the change of PSQI scores between two groups after 3-month treatment. The total PSQI scores range from 0 (sleep well) to 21 (quite poor sleep), reflecting the sleep quality. From baseline to 3-month follow-up visit
Secondary Changes of Tinnitus Handicap Inventory (THI) scores in the two groups for long-term efficacy assessment Difference in changes of THI between two groups from 3-month follow-up visit to 12-month follow-up visit. The THI evaluates the severity of tinnitus in terms of emotion and function. The global scores of THI range from 0 (no disability) to 100 (serve disability). From 3-month follow-up visit to 12-month follow-up visit
Secondary Changes of Visual Analog Scale (VAS) scores in the two groups for long-term efficacy assessment Difference in changes of VAS between two groups from 3-month follow-up visit to 12-month follow-up visit. The total VAS scores range from 0 (negligible) to 10 (too nosiy to tolerate), reflecting the loudness of tinnitus patients feel. From 3-month follow-up visit to 12-month follow-up visit
Secondary Changes of Beck Anxiety Inventory (BAI) scores in the two groups for long-term efficacy assessment Difference in changes of BAI between two groups from 3-month follow-up visit to 12-month follow-up visit. The total BAI scores range from 0 (normal) to 63 (serve anxiety), reflecting the degree of anxiety. From 3-month follow-up visit to 12-month follow-up visit
Secondary Changes of Beck Depression Inventory (BDI) scores in the two groups for long-term efficacy assessment Difference in changes of PSQI between two groups from 3-month follow-up visit to 12-month follow-up visit. The total BDI scores range from 0 (normal) to 63 (serve depression), reflecting the degree of depression. From 3-month follow-up visit to 12-month follow-up visit
Secondary Changes of Pittsburgh sleep quality index (PSQI) scores in the two groups for long-term efficacy assessment Difference in changes of PSQI between two groups from 3-month follow-up visit to 12-month follow-up visit. The total PSQI scores range from 0 (sleep well) to 21 (quite poor sleep), reflecting the sleep quality. From 3-month follow-up visit to 12-month follow-up visit
Secondary The effective rate of relieving chronic subjective tinnitus in the two groups Group effective rate = number of patients in each group who completed 3 months of treatment and whose THI score decreased by = 7 points / number of patients in each group who completed 3 months of treatment. From baseline to 3-month follow-up visit
Secondary The difference of functional connectivity based on resting state electroencephalogram (EEG) between the two groups The difference of functional connectivity based on resting state electroencephalogram (EEG) in the two groups from baseline to 12-month follow-up visit. The functional connectivity is defined as the correlation between two different brain regions based on coherence or phase synchronization. From baseline to 12-month follow-up visit
Secondary The difference of effective connectivity based on resting state electroencephalogram (EEG) between the two groups The difference of effective connectivity based on resting state electroencephalogram (EEG) in the two groups from baseline to 12-month follow-up visit. The effective connectivity is defined as the directed functional connectivity between two brain regions based on granger causality analysis. From baseline to 12-month follow-up visit
Secondary The difference of functional connectivity based on functional magnetic resonance imaging (fMRI) between the two groups The difference of functional connectivity based on functional magnetic resonance imaging (fMRI) in the two groups from baseline to 12-month follow-up visit. The functional connectivity is defined as the Pearson's correlation between two different brain regions. From baseline to 12-month follow-up visit
Secondary The difference of effective connectivity based on functional magnetic resonance imaging (fMRI) between the two groups The difference of effective connectivity based on functional magnetic resonance imaging (fMRI) in the two groups from baseline to 12-month follow-up visit. The effective connectivity is defined as the directed functional connectivity between two brain regions based on granger causality analysis. From baseline to 12-month follow-up visit
See also
  Status Clinical Trial Phase
Recruiting NCT04987502 - Virtual Reality and Subjective Tinnitus N/A
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT04404439 - Treatment of Tinnitus With Migraine Medications Phase 4
Completed NCT03782220 - Effects of Kinesio Taping in Patients With Somatosensory Tinnitus N/A
Completed NCT05711641 - Action of Intra-auricular Topical Lidocaine on Tinnitus N/A
Completed NCT03711630 - Impact of Meditation on Bothersome Tinnitus N/A
Completed NCT05591144 - Short-term Oral Steriods for Acute Tinnitus N/A
Completed NCT04565132 - HD-tDCS as a Treatment for Chronic Tinnitus N/A
Completed NCT02315508 - Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo Phase 2
Active, not recruiting NCT03888521 - Evaluating the GN ReSound Relief App Using task-and Rest-based fMRI N/A
Not yet recruiting NCT05507372 - Treatment for Post Acute COVID-19 Syndrome N/A
Recruiting NCT05198973 - Bumblebee Breath Effect on Tinnitus in Older Patients N/A
Not yet recruiting NCT04623957 - Safety and Efficacy of Acupressure Applied Through ForgTin© in Patients With Tinnitus N/A
Recruiting NCT05964725 - The Study on Effect and Neural Network Mechanism of Transcranial Direct Current Stimulation for Sudden Deafness With Tinnitus N/A
Recruiting NCT04162405 - Tinnitus in Patients With and Without Sensorineural Hearing Loss
Completed NCT03716544 - Efficacy of Amplification With Hearing Aids for Tinnitus Relief N/A
Completed NCT03638986 - Comparison of the Two Validated German Versions of the "Tinnitus Functional Index" for Switzerland and for Germany
Completed NCT04127708 - Tinnitus and Acupuncture N/A
Enrolling by invitation NCT04382807 - Internet-delivered Group Counseling for Chronic Tinnitus
Completed NCT05271825 - Broadband Amplification as Tinnitus Treatment N/A